17 May 2016 - No directly comparative study; the indirect comparisons are unusable.

Brivaracetam (Briviact) was approved in January 2016 for use as adjunctive therapy for young people aged 16 years and adults with seizures. In an early benefit assessment, the IQWiG has investigated whether this drug has an additional benefit over the appropriate comparator therapy.

The manufacturer did not provide any data from a direct comparison study; the indirect comparisons in the dossier are not suitable for deriving an additional benefit for several reasons. Therefore, the IQWiG finds no evidence of an additional benefit of brivaracetam over the appropriate comparator therapy.

For more details, go to: https://www.iqwig.de/de/presse/pressemitteilungen/pressemitteilungen/brivaracetam-bei-epilepsie-zusatznutzen-nicht-belegt.7334.html?&et_cid=4&et_lid=%25208